Integra LifeSciences Reports Third Quarter 2026 Financial Results
Integra LifeSciences reported Q3 2026 revenue of $411.2 million, up 2.3% reported and 2.5% organically, with GAAP EPS of $0.19 and adjusted EPS of $0.59 versus $0.54 a year ago. Results included roughly $7 million of revenue lost to flood damage at the Cincinnati facility; Specialty Surgery grew 4.2% organically while Tissue Reconstruction declined 2.2%. The company generated $96.0 million of operating cash flow, cut net debt to $1.5 billion (3.8x leverage), and completed a $2.1 billion refinancing including $450 million of 9.5% senior secured notes due 2033.
Key figures
- Eps
- 0.19
- Revenue
- 411182000
- Guidance
- FY26 revenue $1.634B-$1.654B, adjusted EPS $2.30-$2.40; Q4 revenue $413M-$433M (reported -5.2% to -0.5%), adjusted EPS $0.61-$0.71
- Revenue Yoy
- 2.3%
- Net debt
- 1516770000
- Liquidity
- 559000000
- Adjusted eps
- 0.59
- Free cash flow
- 85731000
- Leverage ratio
- 3.8x
- Adjusted ebitda
- 79787000
- Gaap net income
- 14852000
- Refi notes rate
- 9.5%
- Debt refinancing
- 2100000000
- Gaap gross margin
- 51.0%
- Adjusted net income
- 46444000
- Operating cash flow
- 95977000
- Adjusted gross margin
- 61.1%
- Adjusted ebitda margin
- 19.4%
- Adjusted eps prior year
- 0.54
- Cincinnati flood revenue impact
- 7000000
AI analysis
Red flags5 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.